Enclomiphene vs Oxandrolone (Anavar)

Mechanism

Enclomiphene is the purified trans-isomer of clomiphene citrate that acts as a selective estrogen receptor antagonist at the hypothalamus and pituitary without the estrogenic agonist activity of the zuclomiphene isomer. By blocking estrogen receptor alpha (ERa) in the hypothalamus, it removes estradiol-mediated negative feedback on GnRH neurons, resulting in increased pulsatile GnRH release and consequent elevation of LH and FSH from the anterior pituitary. This stimulates endogenous Leydig cell testosterone production while preserving spermatogenesis — a critical advantage over exogenous testosterone.

Standard Dosing

Research indicates 12.5-25 mg daily orally for testosterone restoration in secondary hypogonadism.

Timing

Once daily, morning preferred. No food timing requirements. Consistent daily dosing for optimal HPG axis stimulation.

Cycle Duration

Long-term use (months to years) is feasible due to absence of zuclomiphene accumulation issues. Reassess every 3-6 months.

Side Effects

• Headache
• Hot flashes
• Nausea (less common than racemic clomiphene)
• Elevated estradiol (from increased testosterone substrate for aromatase)
• Rare visual disturbances (significantly less than racemic clomiphene)

Contraindications

• Primary hypogonadism (elevated gonadotropins, testicular failure)
• Severe hepatic impairment
• Known hypersensitivity to clomiphene isomers
• Pituitary tumors
• Vision changes or thrombotic history warrant caution

Best Stacking Partners

Mechanism

Oxandrolone is a synthetic 17-alpha-alkylated dihydrotestosterone (DHT) derivative with a modified A-ring (replacement of C2 with an oxygen atom) that confers high anabolic-to-androgenic ratio (~10:1). It enhances protein synthesis by activating the androgen receptor while strongly binding sex hormone-binding globulin (SHBG), increasing free testosterone fraction. Oxandrolone directly stimulates phosphocreatine synthesis in skeletal muscle and has demonstrated anti-catabolic effects through cortisol receptor antagonism. In burn patients, it reverses catabolism by restoring the IGF-1/IGFBP-3 axis.

Standard Dosing

Research indicates 5-20 mg/day orally for therapeutic/recovery applications. Clinical burn protocols use 0.1 mg/kg twice daily.

Timing

Split into 2 doses (morning and evening) due to 9-hour half-life. Take with food to reduce GI discomfort.

Cycle Duration

Typical therapeutic cycles: 6-12 weeks. Clinical burn protocols have extended to 1 year+ with liver monitoring. Limit cycle length to minimize hepatic stress.

Side Effects

• Hepatotoxicity (dose and duration dependent — mild with therapeutic doses)
• Lipid profile disruption (significant HDL suppression, LDL elevation)
• Suppression of endogenous testosterone (dose dependent)
• Virilization in females at higher doses
• Headache
• Nausea
• Potential hair loss in genetically susceptible individuals

Contraindications

• Prostate cancer
• Breast cancer in males
• Hypercalcemia
• Severe hepatic impairment or active liver disease
• Nephrotic syndrome
• Pregnancy (Category X)

Best Stacking Partners